Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice (original) (raw)

• Alanee, S. et al. Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder. World J. Urol. 37, 107–114 (2019).
  Article PubMed Google Scholar
• Cancer Genome Atlas Research Network.Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).
  Article Google Scholar
• van Rhijn, B. W. G. et al. Prognostic value of the WHO1973 and WHO2004/2016 classification systems for grade in primary Ta/T1 non-muscle-invasive bladder cancer: a multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. Eur. Urol. Oncol. 4, 182–191 (2021).
  Article PubMed Google Scholar
• Cambier, S. et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance Bacillus Calmette-Guérin. Eur. Urol. 69, 60–69 (2016).
  Article PubMed Google Scholar
• Oszczudlowski, M. & Dobruch, J. Prediction of progression to muscle-invasive disease in patients with high-risk bladder cancer. Transl. Androl. Urol. 7, 749–751 (2018).
  Article PubMed PubMed Central Google Scholar
• D'Andrea, D. et al. Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: a clinical decision-making tool. Urol. Oncol. 36, 239.e1–239.e7 (2018).
  Article PubMed Google Scholar
• van den Bosch, S. & Witjes, J. A. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur. Urol. 60, 493–500 (2011).
  Article PubMed Google Scholar
• Vlaming, M., Kiemeney, L. & van der Heijden, A. G. Survival after radical cystectomy: progressive versus de novo muscle invasive bladder cancer. Cancer Treat. Res. Commun. 25, 100264 (2020).
  Article PubMed Google Scholar
• Sylvester, R. J. et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur. Urol. 79, 480–488 (2021).
  Article PubMed Google Scholar
• Martini, A. et al. The natural history of untreated muscle-invasive bladder cancer. BJU Int. 125, 270–275 (2020).
  Article PubMed Google Scholar
• Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
  Article PubMed Google Scholar
• Mossanen, M. & Gore, J. L. The burden of bladder cancer care: direct and indirect costs. Curr. Opin. Urol. 24, 487–491 (2014).
  Article PubMed Google Scholar
• Leal, J., Luengo-Fernandez, R., Sullivan, R. & Witjes, J. A. Economic burden of bladder cancer across the European Union. Eur. Urol. 69, 438–447 (2016).
  Article PubMed Google Scholar
• Laaksonen, M. A. et al. The future burden of kidney and bladder cancers preventable by behavior modification in Australia: a pooled cohort study. Int. J. Cancer 146, 874–883 (2020).
  Article CAS PubMed Google Scholar
• Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer 144, 1941–1953 (2019).
  Article CAS PubMed Google Scholar
• International Agency for Research on Cancer. Cancer today. IARC https://gco.iarc.fr/today (2020).
• Antoni, S. et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur. Urol. 71, 96–108 (2017).
  Article PubMed Google Scholar
• Richters, A., Aben, K. K. & Kiemeney, L. A. The global burden of urinary bladder cancer: an update. World J. Urol. 38, 1895–1904 (2020).
  Article PubMed Google Scholar
• Islami, F. et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J. Clin. 68, 31–54 (2018).
  Article PubMed Google Scholar
• US Census Bureau. International database: world population estimates and projections. US Census Bureau https://www.census.gov/programs-surveys/international-programs/about/idb.html (2021).
• Reitsma, M. B. et al. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet 389, 1885–1906 (2017).
  Article Google Scholar
• Ince Yenilmez, M. Economic and social consequences of population aging the dilemmas and opportunities in the twenty-first century. Appl. Res. Qual. Life 10, 735–752 (2015).
  Article Google Scholar
• Szabo, S. et al. Health workforce demography: a framework to improve understanding of the health workforce and support achievement of the Sustainable Development Goals. Hum. Resour. Health 18, 7 (2020).
  Article PubMed PubMed Central Google Scholar
• Chhaya, S. et al. Role of perioperative immune checkpoint inhibitors in muscle invasive bladder cancer. Oncol. Ther. 11, 49–64 (2023).
  Article PubMed PubMed Central Google Scholar
• Ward Grados, D. F., Ahmadi, H., Griffith, T. S. & Warlick, C. A. Immunotherapy for bladder cancer: latest advances and ongoing clinical trials. Immunol. Invest. 51, 2226–2251 (2022).
  Article CAS PubMed Google Scholar
• Necchi, A. et al. Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study. J. Clin. Oncol. 36, 3353–3360 (2018).
  Article CAS PubMed Google Scholar
• van Dorp, J. et al. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. Nat. Med. https://doi.org/10.1038/s41591-022-02199-y (2023).
  Article PubMed Google Scholar
• Kantor, A. F., Hartge, P., Hoover, R. N. & Fraumeni, J. F. Jr Epidemiological characteristics of squamous cell carcinoma and adenocarcinoma of the bladder. Cancer Res. 48, 3853–3855 (1988).
  CAS PubMed Google Scholar
• Vineis, P. et al. DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int. J. Cancer 65, 314–316 (1996).
  Article CAS PubMed Google Scholar
• Bellamri, M. et al. DNA damage and oxidative stress of tobacco smoke condensate in human bladder epithelial cells. Chem. Res. Toxicol. 35, 1863–1880 (2022).
  Article CAS PubMed Google Scholar
• Lee, H. W. et al. Acrolein- and 4-aminobiphenyl-DNA adducts in human bladder mucosa and tumor tissue and their mutagenicity in human urothelial cells. Oncotarget 5, 3526–3540 (2014).
  Article PubMed PubMed Central Google Scholar
• Cumberbatch, M. G., Rota, M., Catto, J. W. & La Vecchia, C. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur. Urol. 70, 458–466 (2016).
  Article CAS PubMed Google Scholar
• Kogevinas M., Figueroa, J., Garcia-Closas M. & Mucci, L. in Textbook of Cancer Epidemiology 3rd edn (eds Adami, H. O. et al.) 543–570 (Oxford Univ. Press, 2018).
• Fortuny, J. et al. Tobacco, occupation and non‐transitional‐cell carcinoma of the bladder: an international case‐control study. Int. J. Cancer 80, 44–46 (1999).
  Article CAS PubMed Google Scholar
• Kogevinas, M., Garcia-Closas, M. & Trichopoulos D. in Textbook of Cancer Epidemiology 2nd edn (eds Adami, H.-O. et al.) 573–596 (Oxford Univ. Press, 2008).
• van Osch, F. H., Jochems, S. H., van Schooten, F. J., Bryan, R. T. & Zeegers, M. P. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int. J. Epidemiol. 45, 857–870 (2016).
  Article PubMed Google Scholar
• IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco Smoke and Involuntary Smoking (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans Vol. 83) (IARC, 2004).
• Freedman, N. D., Silverman, D. T., Hollenbeck, A. R., Schatzkin, A. & Abnet, C. C. Association between smoking and risk of bladder cancer among men and women. JAMA 306, 737–745 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Bjurlin, M. A. et al. Carcinogen biomarkers in the urine of electronic cigarette users and implications for the development of bladder cancer: a systematic review. Eur. Urol. Oncol. 4, 766–783 (2021).
  Article PubMed Google Scholar
• Christoforidou, E. P. et al. Bladder cancer and arsenic through drinking water: a systematic review of epidemiologic evidence. J. Environ. Sci. Health A Tox Hazard. Subst. Environ. Eng. 48, 1764–1775 (2013).
  Article CAS PubMed Google Scholar
• Carattino, M. D. et al. Bladder filling and voiding affect umbrella cell tight junction organization and function. Am. J. Physiol. Renal Physiol. 305, F1158–F1168 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Kwan, M. L., Garren, B., Nielsen, M. E. & Tang, L. Lifestyle and nutritional modifiable factors in the prevention and treatment of bladder cancer. Urol. Oncol. 37, 380–386 (2019).
  Article PubMed Google Scholar
• Al-Zalabani, A. H., Stewart, K. F., Wesselius, A., Schols, A. M. & Zeegers, M. P. Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses. Eur. J. Epidemiol. 31, 811–851 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Vrieling, A. Lifestyle and bladder cancer prevention: no consistent evidence from cohort studies. Eur. J. Epidemiol. 32, 1033–1035 (2017).
  Article PubMed Google Scholar
• World Cancer Research Fund. Continuous Update Project Expert Report 2018. Diet, nutrition, physical activity and bladder cancer. WCRF, https://www.wcrf.org/wp-content/uploads/2021/02/Summary-of-Third-Expert-Report-2018.pdf (2018).
• Sun, J. W. et al. Obesity and risk of bladder cancer: a dose-response meta-analysis of 15 cohort studies. PLoS ONE 10, e0119313 (2015).
  Article PubMed PubMed Central Google Scholar
• Keimling, M., Behrens, G., Schmid, D., Jochem, C. & Leitzmann, M. F. The association between physical activity and bladder cancer: systematic review and meta-analysis. Br. J. Cancer 110, 1862–1870 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Krabbe, L. M., Svatek, R. S., Shariat, S. F., Messing, E. & Lotan, Y. Bladder cancer risk: use of the PLCO and NLST to identify a suitable screening cohort. Urol. Oncol. 33, 65.e19–65.e25 (2015).
  Article PubMed Google Scholar
• Hartge, P. et al. Unexplained excess risk of bladder cancer in men. J. Natl Cancer Inst. 82, 1636–1640 (1990).
  Article CAS PubMed Google Scholar
• Lam, C. M., Li, Z., Theodorescu, D. & Li, X. Mechanism of sex differences in bladder cancer: evident and elusive sex-biasing factors. Bladder Cancer 8, 241–254 (2022).
  Article PubMed PubMed Central Google Scholar
• Zhang, Y. Understanding the gender disparity in bladder cancer risk: the impact of sex hormones and liver on bladder susceptibility to carcinogens. J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev. 31, 287–304 (2013).
  Article CAS PubMed Google Scholar
• Buckley, D. B. & Klaassen, C. D. Tissue-and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice. Drug Metab. Dispos. 35, 121–127 (2007).
  Article CAS PubMed Google Scholar
• Dobruch, J. et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur. Urol. 69, 300–310 (2016).
  Article PubMed Google Scholar
• Daugherty, S. E. et al. Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH‐AARP Diet and Health Study. Int. J. Cancer 133, 462–472 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Fajkovic, H. et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J. Urol. 29, 457–463 (2011).
  Article PubMed Google Scholar
• Richters, A. et al. Bladder cancer survival: women only fare worse in the first two years after diagnosis. Urol. Oncol. 37, 853–861 (2019).
  Article CAS PubMed Google Scholar
• Garg, T. et al. Gender disparities in hematuria evaluation and bladder cancer diagnosis: a population based analysis. J. Urol. 192, 1072–1077 (2014).
  Article PubMed PubMed Central Google Scholar
• Cohn, J. A., Vekhter, B., Lyttle, C., Steinberg, G. D. & Large, M. C. Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims‐based investigation. Cancer 120, 555–561 (2014).
  Article PubMed Google Scholar
• Johnson, E. K., Daignault, S., Zhang, Y. & Lee, C. T. Patterns of hematuria referral to urologists: does a gender disparity exist? Urology 72, 498–502 (2008).
  Article PubMed Google Scholar
• Buteau, A. et al. What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up. Urol. Oncol. 32, 128–134 (2014).
  Article PubMed Google Scholar
• Volikova, A. I. et al. Structural, biomechanical and hemodynamic assessment of the bladder wall in healthy subjects. Res. Rep. Urol. 11, 233–245 (2019).
  PubMed PubMed Central Google Scholar
• Scosyrev, E., Noyes, K., Feng, C. & Messing, E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 115, 68–74 (2009).
  Article PubMed Google Scholar
• Richters, A., Leliveld, A. M., Goossens-Laan, C. A., Aben, K. K. & Özdemir, B. C. Sex differences in treatment patterns for non-advanced muscle-invasive bladder cancer: a descriptive analysis of 3484 patients of the Netherlands Cancer Registry. World J. Urol. 40, 2275–2281 (2022).
  Article PubMed PubMed Central Google Scholar
• Özdemir, B. C., Csajka, C., Dotto, G.-P. & Wagner, A. D. Sex differences in efficacy and toxicity of systemic treatments: an undervalued issue in the era of precision oncology. J. Clin. Oncol. 36, 2680–2683 (2018).
  Article PubMed Google Scholar
• Aben, K. K. et al. Absence of karyotype abnormalities in patients with familial urothelial cell carcinoma. Urology 57, 266–269 (2001).
  Article CAS PubMed Google Scholar
• Marees, T. et al. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J. Natl Cancer Inst. 100, 1771–1779 (2008).
  Article PubMed Google Scholar
• Kleinerman, R. A. et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J. Clin. Oncol. 23, 2272–2279 (2005).
  Article PubMed Google Scholar
• Fletcher, O. et al. Lifetime risks of common cancers among retinoblastoma survivors. J. Natl Cancer Inst. 96, 357–363 (2004).
  Article PubMed Google Scholar
• Schonfeld, S. J. et al. Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors. Br. J. Cancer 124, 1312–1319 (2021).
  Article CAS PubMed PubMed Central Google Scholar
• Gripp, K. W. Tumor predisposition in Costello syndrome. Am. J. Med. Genet. C. Semin. Med. Genet. 137c, 72–77 (2005).
  Article PubMed Google Scholar
• van der Post, R. S. et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J. Med. Genet. 47, 464–470 (2010).
  Article PubMed Google Scholar
• Skeldon, S. C. et al. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur. Urol. 63, 379–385 (2013).
  Article CAS PubMed Google Scholar
• Pietzak, E. J. et al. Inherited germline cancer susceptibility gene variants in individuals with non-muscle-invasive bladder cancer. Clin. Cancer Res. 28, 4267–4277 (2022).
  Article CAS PubMed PubMed Central Google Scholar
• Yap, T. A. et al. Prevalence of germline findings among tumors from cancer types lacking hereditary testing guidelines. JAMA Netw. Open 5, e2213070 (2022).
  Article PubMed PubMed Central Google Scholar
• Zeng, C. et al. Association of pathogenic variants in hereditary cancer genes with multiple diseases. JAMA Oncol. 8, 835–844 (2022).
  Article PubMed Google Scholar
• Vosoughi, A. et al. Common germline-somatic variant interactions in advanced urothelial cancer. Nat. Commun. 11, 6195 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Nassar, A. H. et al. Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genet. Med. 22, 709–718 (2020).
  Article CAS PubMed Google Scholar
• Carlo, M. I. et al. Cancer susceptibility mutations in patients with urothelial malignancies. J. Clin. Oncol. 38, 406–414 (2020).
  Article CAS PubMed Google Scholar
• Aben, K. K. et al. Familial aggregation of urothelial cell carcinoma. Int. J. Cancer 98, 274–278 (2002).
  Article CAS PubMed Google Scholar
• de Maturana, E. L. et al. Bladder cancer genetic susceptibility. A systematic review. Bladder Cancer 4, 215–226 (2018).
  Article PubMed PubMed Central Google Scholar
• Figueroa, J. D. et al. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum. Mol. Genet. 25, 1203–1214 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Marcus, P. M. et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol. Biomark. Prev. 9, 461–467 (2000).
  CAS Google Scholar
• Figueroa, J. D. et al. Genome-wide interaction study of smoking and bladder cancer risk. Carcinogenesis 35, 1737–1744 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Loomis, D., Guha, N., Hall, A. L. & Straif, K. Identifying occupational carcinogens: an update from the IARC Monographs. Occup. Environ. Med. 75, 593–603 (2018).
  Article PubMed Google Scholar
• Cumberbatch, M. G. K. et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur. Urol. 74, 784–795 (2018).
  Article PubMed Google Scholar
• Baris, D. et al. Elevated bladder cancer in northern New England: the role of drinking water and arsenic. J. Natl Cancer Inst. 108, djw099 (2016).
  Article PubMed PubMed Central Google Scholar
• Nigra, A. E. et al. Inequalities in public water arsenic concentrations in counties and community water systems across the United States, 2006–2011. Environ. Health Perspect. 128, 127001 (2020).
  Article PubMed PubMed Central Google Scholar
• Kurttio, P., Pukkala, E., Kahelin, H., Auvinen, A. & Pekkanen, J. Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ. Health Perspect. 107, 705–710 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Villanueva, C. M. et al. Global assessment of chemical quality of drinking water: the case of trihalomethanes. Water Res. 230, 119568 (2023).
  Article CAS PubMed Google Scholar
• Villanueva, C. M., Fernandez, F., Malats, N., Grimalt, J. O. & Kogevinas, M. Meta-analysis of studies on individual consumption of chlorinated drinking water and bladder cancer. J. Epidemiol. Community Health 57, 166–173 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Diana, M., Felipe-Sotelo, M. & Bond, T. Disinfection byproducts potentially responsible for the association between chlorinated drinking water and bladder cancer: a review. Water Res. 162, 492–504 (2019).
  Article CAS PubMed Google Scholar
• European Environment Agency. Beating cancer – the role of Europe’s environment. European Envrionment Agency https://www.eea.europa.eu/publications/environmental-burden-of-cancer/beating-cancer-the-role-of-europes (2023).
• Williams, S. B. et al. Proximity to oil refineries and risk of cancer: a population-based analysis. JNCI Cancer Spectr. 4, pkaa088 (2020).
  Article PubMed PubMed Central Google Scholar
• Pedersen, M. et al. Is there an association between ambient air pollution and bladder cancer incidence? Analysis of 15 European cohorts. Eur. Urol. Focus. 4, 113–120 (2018).
  Article PubMed Google Scholar
• Lackey, E. K. & Horrall, S. Schistosomiasis (StatPearls, 2022).
• Salem, S., Mitchell, R. E., El‐Alim El‐Dorey, A., Smith, J. A. & Barocas, D. A. Successful control of schistosomiasis and the changing epidemiology of bladder cancer in Egypt. BJU Int. 107, 206–211 (2011).
  Article PubMed Google Scholar
• Bedwani, R. et al. Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt. Br. J. Cancer 77, 1186–1189 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Aula, O. P., McManus, D. P., Jones, M. K. & Gordon, C. A. Schistosomiasis with a focus on Africa. Trop. Med. Infect. Dis. 6, 109 (2021).
  Article PubMed PubMed Central Google Scholar
• Zhu, Z. et al. Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies. BMC Cancer 13, 310 (2013).
  Article PubMed PubMed Central Google Scholar
• Tuccori, M. et al. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ 352, i1541 (2016).
  Article PubMed PubMed Central Google Scholar
• Groah, S. L. et al. Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch. Phys. Med. Rehabil. 83, 346–351 (2002).
  Article PubMed Google Scholar
• American College of Surgeons. Best Practice Guidelines: Spine Injury (American College of Surgeons, 2022).
• Welk, B., McIntyre, A., Teasell, R., Potter, P. & Loh, E. Bladder cancer in individuals with spinal cord injuries. Spinal Cord. 51, 516–521 (2013).
  Article CAS PubMed Google Scholar
• Yu, Z. et al. The risk of bladder cancer in patients with urinary calculi: a meta-analysis. Urolithiasis 46, 573–579 (2018).
  Article PubMed Google Scholar
• IARC. Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. IARC Monogr. Eval. Carcinog. Risks Hum. Suppl. 7, 1–440 (1987).
  Google Scholar
• Laursen, B. Cancer of the bladder in patients treated with chlornaphazine. Br. Med. J. 3, 684–685 (1970).
  Article CAS PubMed PubMed Central Google Scholar
• Thiede, T. & Christensen, B. C. Bladder tumors induced by chlornaphazine treatment [Danish]. Ugeskr. Laeger 137, 661–666 (1975).
  CAS PubMed Google Scholar
• Fortuny, J. et al. Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol. 7, 13 (2007).
  Article PubMed PubMed Central Google Scholar
• McCredie, M., Stewart, J. H., Ford, J. M. & MacLennan, R. A. Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. Br. J. Urol. 55, 220–224 (1983).
  Article CAS PubMed Google Scholar
• Antoni, S. et al. The ban on phenacetin is associated with changes in the incidence trends of upper-urinary tract cancers in Australia. Aust. N. Z. J. Public Health 38, 455–458 (2014).
  Article PubMed Google Scholar
• Chou, W. H. et al. Cyclophosphamide-associated bladder cancers and considerations for survivorship care: a systematic review. Urol. Oncol. 39, 678–685 (2021).
  Article CAS PubMed Google Scholar
• Sountoulides, P., Koletsas, N., Kikidakis, D., Paschalidis, K. & Sofikitis, N. Secondary malignancies following radiotherapy for prostate cancer. Ther. Adv. Urol. 2, 119–125 (2010).
  Article PubMed PubMed Central Google Scholar
• Jahreiß, M.-C. et al. The risk of second primary cancers in prostate cancer survivors treated in the modern radiotherapy era. Front. Oncol. 10, 605119 (2020).
  Article PubMed PubMed Central Google Scholar
• Murray, L., Henry, A., Hoskin, P., Siebert, F.-A. & Venselaar, J. PROBATE group of GEC ESTRO Second primary cancers after radiation for prostate cancer: a systematic review of the clinical data and impact of treatment technique. Radiother. Oncol. 110, 213–228 (2014).
  Article PubMed PubMed Central Google Scholar
• Alguacil, J. et al. Urinary pH, cigarette smoking and bladder cancer risk. Carcinogenesis 32, 843–847 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Rink, M. et al. Smoking reduces the efficacy of intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer. Eur. Urol. 62, 1204–1206 (2012).
  Article PubMed Google Scholar
• Sfakianos, J. P., Shariat, S. F., Favaretto, R. L., Rioja, J. & Herr, H. W. Impact of smoking on outcomes after intravesical bacillus Calmette-Guerin therapy for urothelial carcinoma not invading muscle of the bladder. BJU Int. 108, 526–530 (2011).
  Article CAS PubMed Google Scholar
• Cacciamani, G. E. et al. Association between smoking exposure, neoadjuvant chemotherapy response and survival outcomes following radical cystectomy: systematic review and meta-analysis. J. Urol. 204, 649–660 (2020).
  Article CAS PubMed Google Scholar
• Rink, M. et al. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. Eur. Urol. 64, 456–464 (2013).
  Article PubMed Google Scholar
• Haeuser, L. et al. The impact of smoking on radical cystectomy complications increases in elderly patients. Cancer 127, 1387–1394 (2021).
  Article PubMed Google Scholar
• Lauridsen, S. V. et al. Effect of a smoking and alcohol cessation intervention initiated shortly before radical cystectomy – the STOP-OP study: a randomised clinical trial. Eur. Urol. Focus 8, 1650–1658 (2022).
  Article PubMed Google Scholar
• van Osch, F. H., Jochems, S. H., van Schooten, F. J., Bryan, R. T. & Zeegers, M. P. Significant role of lifetime cigarette smoking in worsening bladder cancer and upper tract urothelial carcinoma prognosis: a meta-analysis. J. Urol. 195, 872–879 (2016).
  Article PubMed Google Scholar
• Hou, L. et al. Association of smoking status with prognosis in bladder cancer: a meta-analysis. Oncotarget 8, 1278–1289 (2017).
  Article PubMed Google Scholar
• Fleshner, N. et al. Influence of smoking status on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma of the bladder. Cancer 86, 2337–2345 (1999).
  Article CAS PubMed Google Scholar
• Chen, C. H. et al. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int. 100, 281–286 (2007).
  Article PubMed Google Scholar
• Lu, Y. & Tao, J. Diabetes mellitus and obesity as risk factors for bladder cancer prognosis: a systematic review and meta-analysis. Front. Endocrinol. 12, 699732 (2021).
  Article Google Scholar
• Hu, X. et al. The prognostic value of sarcopenia in patients with surgically treated urothelial carcinoma: a systematic review and meta-analysis. Eur. J. Surg. Oncol. 45, 747–754 (2019).
  Article PubMed Google Scholar
• Tobert, C. M. et al. Emerging impact of malnutrition on surgical patients: literature review and potential implications for cystectomy in bladder cancer. J. Urol. 198, 511–519 (2017).
  Article PubMed PubMed Central Google Scholar
• Alam, S. M. et al. Optimizing nutritional status in patients undergoing radical cystectomy: a systematic scoping review. Bladder Cancer 7, 449–461 (2021).
  Article PubMed PubMed Central Google Scholar
• Hamilton-Reeves, J. et al. A randomized phase III double-blind clinical trial (S1600) evaluating the effect of immune-enhancing nutrition on radical cystectomy outcomes [abstract]. J. Clin. Oncol. 36 (Suppl. 6), TPS529 (2018).
  Article Google Scholar
• Westhoff, E. et al. Body mass index, diet-related factors, and bladder cancer prognosis: a systematic review and meta-analysis. Bladder Cancer 4, 91–112 (2018).
  Article PubMed PubMed Central Google Scholar
• Zuniga, K. B. et al. Lifestyle and non-muscle invasive bladder cancer recurrence, progression, and mortality: available research and future directions. Bladder Cancer 6, 9–23 (2020).
  Article PubMed PubMed Central Google Scholar
• Michalek, A. M., Cummings, K. M. & Phelan, J. Vitamin A and tumor recurrence in bladder cancer. Nutr. Cancer 9, 143–146 (1987).
  Article CAS PubMed Google Scholar
• Donat, S. M., Bayuga, S., Herr, H. W. & Berwick, M. Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer. J. Urol. 170, 1777–1780 (2003).
  Article PubMed Google Scholar
• Jochems, S. H. J. et al. Total fluid intake and the risk of recurrence in patients with non-muscle invasive bladder cancer: a prospective cohort study. Bladder Cancer 4, 303–310 (2018).
  Article PubMed PubMed Central Google Scholar
• Wakai, K., Ohno, Y., Obata, K. & Aoki, K. Prognostic significance of selected lifestyle factors in urinary bladder cancer. Jpn. J. Cancer Res. 84, 1223–1229 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Tang, L. et al. Intake of cruciferous vegetables modifies bladder cancer survival. Cancer Epidemiol. Biomark. Prev. 19, 1806–1811 (2010).
  Article CAS Google Scholar
• Jochems, S. H. J. et al. Fruit and vegetable intake and the risk of recurrence in patients with non-muscle invasive bladder cancer: a prospective cohort study. Cancer Causes Control. 29, 573–579 (2018).
  Article PubMed PubMed Central Google Scholar
• Westhoff, E. et al. Dietary patterns and risk of recurrence and progression in non-muscle-invasive bladder cancer. Int. J. Cancer 142, 1797–1804 (2018).
  Article CAS PubMed Google Scholar
• Benhamou, S. et al. A prospective multicenter study on bladder cancer: the COBLAnCE cohort. BMC Cancer 16, 837 (2016).
  Article PubMed PubMed Central Google Scholar
• de Goeij, L. et al. The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life. BMJ Open 9, e030396 (2019).
  Article PubMed PubMed Central Google Scholar
• Kwan, M. L. et al. The Be-Well Study: a prospective cohort study of lifestyle and genetic factors to reduce the risk of recurrence and progression of non-muscle-invasive bladder cancer. Cancer Causes Control. 30, 187–193 (2019).
  Article PubMed PubMed Central Google Scholar
• Jensen, B. T., Lauridsen, S. V. & Jensen, J. B. Prehabilitation for major abdominal urologic oncology surgery. Curr. Opin. Urol. 28, 243–250 (2018).
  Article PubMed Google Scholar
• Rammant, E. et al. Understanding physical activity behavior in patients with bladder cancer before and after radical cystectomy: a qualitative interview study. Clin. Rehabil. 33, 750–761 (2019).
  Article PubMed Google Scholar
• Arthuso, F. Z., Fairey, A. S., Boule, N. G. & Courneya, K. S. Bladder cancer and exercise training during intravesical therapy-the BRAVE trial: a study protocol for a prospective, single-centre, phase II randomised controlled trial. BMJ Open 11, e055782 (2021).
  Article PubMed PubMed Central Google Scholar
• Bessa, A. et al. Is there a role for physical activity interventions in the treatment pathway of bladder cancer? A scoping review of the literature. BMJ Open Sport. Exerc. Med. 7, e000951 (2021).
  Article PubMed PubMed Central Google Scholar
• Minnella, E. M. et al. Multimodal prehabilitation to enhance functional capacity following radical cystectomy: a randomized controlled trial. Eur. Urol. Focus. 7, 132–138 (2021).
  Article PubMed Google Scholar
• World Health Organization. WHO Framework Convention on Tobacco Control (WHO, 2003).
• World Health Organization. WHO Report on the Global Tobacco Epidemic, 2021: Addressing New and Emerging Products (WHO, 2021).
• Federal Trade Commission. Federal Trade Commission Cigarette Report for 2019 (FTC, 2021).
• Dai, X., Gakidou, E. & Lopez, A. D. Evolution of the global smoking epidemic over the past half century: strengthening the evidence base for policy action. Tob. Control. 31, 129–137 (2022).
  Article PubMed Google Scholar
• Feirman, S. P. et al. Computational models used to assess us tobacco control policies. Nicotine Tob. Res. 19, 1257–1267 (2017).
  Article PubMed Google Scholar
• Gilbert, A. &, Cornuz, J. Which are the Most Effective and Cost-effective Interventions for Tobacco Control? (WHO, 2003).
• Flor, L. S., Reitsma, M. B., Gupta, V., Ng, M. & Gakidou, E. The effects of tobacco control policies on global smoking prevalence. Nat. Med. 27, 239–243 (2021).
  Article CAS PubMed PubMed Central Google Scholar
• Cumberbatch, M. G., Cox, A., Teare, D. & Catto, J. W. Contemporary occupational carcinogen exposure and bladder cancer: a systematic review and meta-analysis. JAMA Oncol. 1, 1282–1290 (2015).
  Article PubMed Google Scholar
• European Agency for Safety and Health at Work. Directive 2004/37/EC – carcinogens, mutagens or reprotoxic substances at work (European Commission, 2004).
• Babjuk, M. et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur. Urol. 81, 75–94 (2022).
  Article PubMed Google Scholar
• Soukup, V. et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur. Urol. 62, 290–302 (2012).
  Article PubMed Google Scholar
• Petrelli, F., Giannatempo, P., Maccagnano, C., Contieri, R. & Hurle, R. Active surveillance for non-muscle invasive bladder cancer: a systematic review and pooled-analysis. Cancer Treat. Res. Commun. 27, 100369 (2021).
  Article PubMed Google Scholar
• van Valenberg, F. J. P. et al. Prospective validation of an mRNA-based urine test for surveillance of patients with bladder cancer. Eur. Urol. 75, 853–860 (2019).
  Article PubMed Google Scholar
• Cancel-Tassin, G. et al. Assessment of Xpert bladder cancer monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up. World J. Urol. 39, 3329–3335 (2021).
  Article CAS PubMed PubMed Central Google Scholar
• Witjes, J. A. et al. Performance of the bladder EpiCheck™ methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial. Eur. Urol. Oncol. 1, 307–313 (2018).
  Article PubMed Google Scholar
• Kausch, I. et al. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies. Eur. Urol. 57, 595–606 (2010).
  Article PubMed Google Scholar
• Mowatt, G. et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: systematic review and meta-analysis. Int. J. Technol. Assess. Health Care 27, 3–10 (2011).
  Article PubMed Google Scholar
• Veeratterapillay, R. et al. Time to turn on the blue lights: a systematic review and meta-analysis of photodynamic diagnosis for bladder cancer. Eur. Urol. Open. Sci. 31, 17–27 (2021).
  Article PubMed PubMed Central Google Scholar
• Williams, S. B., Gavaghan, M. B., Fernandez, A., Daneshmand, S. & Kamat, A. M. Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer. Urol. Oncol. 40, 10.e7–10.e12 (2022).
  Article PubMed Google Scholar
• Burger, M. et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur. Urol. 64, 846–854 (2013).
  Article PubMed Google Scholar
• Russo, G. I. et al. Performance of narrow band imaging (NBI) and photodynamic diagnosis (PDD) fluorescence imaging compared to white light cystoscopy (WLC) in detecting non-muscle invasive bladder cancer: a systematic review and lesion-level diagnostic meta-analysis. Cancers 13, 4378 (2021).
  Article CAS PubMed PubMed Central Google Scholar
• Wilson, J. M. G. & Jungner, G. Principles and Practice of Screening for Disease (WHO, 1966).
• World Health Organization. A Short Guide to Cancer Screening: Increase Effectiveness, Maximize Benefits and Minimize Harm (WHO, 2022).
• Messing, E. M. et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107, 2173–2179 (2006).
  Article PubMed Google Scholar
• Madeb, R. & Messing, E. M. Long-term outcome of home dipstick testing for hematuria. World J. Urol. 26, 19–24 (2008).
  Article PubMed Google Scholar
• Roobol, M. J., Bangma, C. H., el Bouazzaoui, S., Franken-Raab, C. G. & Zwarthoff, E. C. Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project). Urol. Oncol. 28, 686–690 (2010).
  Article CAS PubMed Google Scholar
• Bangma, C. H. et al. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers. Eur. Urol. 64, 41–47 (2013).
  Article PubMed Google Scholar
• Steiner, H. et al. Early results of bladder-cancer screening in a high-risk population of heavy smokers. BJU Int. 102, 291–296 (2008).
  Article PubMed Google Scholar
• Lotan, Y., Capitanio, U., Shariat, S. F., Hutterer, G. C. & Karakiewicz, P. I. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. BJU Int. 103, 1368–1374 (2009).
  Article CAS PubMed Google Scholar
• Starke, N., Singla, N., Haddad, A. & Lotan, Y. Long-term outcomes in a high-risk bladder cancer screening cohort. BJU Int. 117, 611–617 (2016).
  Article PubMed Google Scholar
• Lotan, Y. et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J. Urol. 182, 52–57 (2009).
  Article PubMed Google Scholar
• Ward, E. et al. Screening workers exposed to 4,4′-methylenebis(2-chloroaniline) for bladder cancer by cystoscopy. J. Occup. Med. 32, 865–868 (1990).
  Article CAS PubMed Google Scholar
• Chen, H. I. et al. Bladder cancer screening and monitoring of 4,4′-methylenebis(2-chloroaniline) exposure among workers in Taiwan. Urology 66, 305–310 (2005).
  Article PubMed Google Scholar
• Giberti, C., Gallo, F., Schenone, M. & Genova, A. Early results of urothelial carcinoma screening in a risk population of coke workers: urothelial carcinoma among coke workers. Biomed. Environ. Sci. 23, 300–304 (2010).
  Article CAS PubMed Google Scholar
• Marsh, G. M. & Cassidy, L. D. The Drake Health Registry Study: findings from fifteen years of continuous bladder cancer screening. Am. J. Ind. Med. 43, 142–148 (2003).
  Article PubMed Google Scholar
• Pesch, B. et al. Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. Int. Arch. Occup. Environ. Health 87, 715–724 (2014).
  Article CAS PubMed Google Scholar
• Sbizzera, M., Descotes, F., Arber, T., Neuville, P. & Ruffion, A. Bladder cancer detection in patients with neurogenic bladder: are cystoscopy and cytology effective, and are biomarkers pertinent as future diagnostic tools? A scoping review. World J. Urol. 40, 1897–1913 (2022).
  Article CAS PubMed Google Scholar
• US Preventive Services Task Force Summaries for patients: screening for bladder cancer: recommendations from the U.S. Preventive Services Task Force. Ann. Intern. Med. 155, 246–251 (2011).
  Article Google Scholar
• Chang, S. S. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J. Urol. 196, 1021–1029 (2016).
  Article PubMed Google Scholar
• Larré, S. et al. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur. Urol. 63, 1049–1058 (2013).
  Article PubMed Google Scholar
• Grossman, H. B. et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293, 810–816 (2005).
  Article CAS PubMed Google Scholar
• Hill, A. B. The environment and disease: association or causation? Proc. R. Soc. Med. 58, 295–300 (1965).
  CAS PubMed PubMed Central Google Scholar
• Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 25–41 (2015).
  Article CAS PubMed Google Scholar
• World Health Organization. WHO Global Report on Trends in Prevalence of Tobacco Smoking 2015 (WHO, 2015).
• World Health Organization. WHO Report on the Global Tobacco Epidemic, 2017: Monitoring Tobacco Use and Prevention Policies (WHO, 2017).